{
  "docId": "019de073-9f6d-75d9-b724-0b887fde2468",
  "docSlug": "f957aa564e21bc93d4cc30c084ec8efa",
  "documentTitle": "Aldeyra Therapeutics | Results Presentation Deck | 13 slides",
  "authorId": "aldeyra-therapeutics",
  "authorName": "Aldeyra Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 13,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "other",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide outlines a clinical trial protocol with two study arms (ADX-2191 vs. routine care) over a 6-month period.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-9f6d-75d9-b724-0b887fde2468/8",
  "deckHref": "/decks/019de073-9f6d-75d9-b724-0b887fde2468",
  "deckJsonHref": "/decks/019de073-9f6d-75d9-b724-0b887fde2468.json",
  "deckAnchorHref": "/decks/019de073-9f6d-75d9-b724-0b887fde2468#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.65,
        "y": 0.35
      },
      "kind": "chart",
      "text": "ADX-2191 added to routine surgical care (n = 68) vs Routine surgical care (n = 38)",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c31a18e2-0fa7-4bcf-afa6-507eecad7f86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.35,
        "y": 0.4
      },
      "kind": "list",
      "text": "Primary Endpoint: Retinal re-detachments due to PVR requiring re-operation within 6 months vs. historical control",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d206c52-073f-49a9-aae0-79bb90d9a8cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.35,
        "y": 0.7
      },
      "kind": "list",
      "text": "Exploratory Endpoints: Macular thickness, epiretinal membrane formation, hypotony vs. routine surgical care",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "186d21c9-9d63-4972-bf93-a6ee9bfb2a32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.35,
        "y": 0.55
      },
      "kind": "list",
      "text": "Secondary Endpoints: Retinal re-detachments due to PVR vs. routine surgical care; Visual acuity vs. routine surgical care",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21d38896-3e66-40c8-bc97-27270c024cd7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "list",
      "text": "Dosing Regimen: At surgery, weekly (x8), and then every other week (x4) intravitreal injections",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d5221b7-d560-4358-84f5-d2e8fcb3b520",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "Design: Multi-center Phase 3 clinical trial of ADX-2191 vs. historical control and routine surgical care",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7b9dc86-4f61-441a-9a88-8a8932a8c36b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "list",
      "text": "Inclusion Highlights: Recurrent retinal detachment due to PVR, or Retinal detachment associated with open-globe injury",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d760a84e-64cd-4b78-a21f-a238b4a0af9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Primary Objective: Evaluate efficacy of intravitreal ADX-2191 injections for prevention of PVR-associated retinal detachment to estimate statistical power for Part 2 of GUARD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6fb2e3f-ca4d-4d74-a379-b7f6214e8599",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Includes 41 subjects enrolled under the open-label portion of the protocol. Ophthalmology 124(6):757-767, 2017; Archives of Ophthalmology 25(9):1161-7, 2007. PVR = proliferative vitreoretinopathy. Hypotony = intraocular pressure less than 5 mm Hg. ADX-2191 (methotrexate injection, USP) for intravitreal administration is an investigational drug candidate.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "543b308b-b8d7-4626-82a1-79059a026b16",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ADX-2191: Design of Part 1 of the Adaptive Phase 3 GUARD Trial in Proliferative Vitreoretinopathy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af9d1ca3-3765-4fd7-922c-cba554a8a2b4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "2a8c4561-5297-42f7-92e4-2461202c37d0",
      "evidence": "Primary Objective: Evaluate efficacy of intravitreal ADX-2191 injections for prevention of PVR-associated retinal detachment to estimate statistical power for Part 2 of GUARD",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}